Oric Pharmaceuticals, Inc. 4

CFO Dominic Piscitelli of Oric Pharmaceuticals, Inc. exercised 77,000 stock options and sold all 77,000 resulting common shares for approximately $1.05 million on August 26, 2026 under a Rule 10b5-1 plan.

On August 26, 2026, Oric Pharmaceuticals, Inc. CFO Dominic Piscitelli exercised two stock option grants for a total of 77,000 shares of common stock (52,000 at $4.36 and 25,000 at $6.00) and immediately sold all 77,000 shares at an average price of $13.6859 under a pre-arranged Rule 10b5-1 trading plan. The option exercises themselves were reported at $0 in the derivative table (standard Form 4 reporting convention), while the common stock transaction table shows the resulting acquisitions from option exercises and the subsequent disposition via open market sale. After these transactions, Piscitelli’s direct beneficial ownership stands at 69,828 shares of common stock, which includes 1,680 shares acquired under the company’s 2020 Employee Stock Purchase Plan; based on the sale price of $13.6859, his post-transaction common stock holdings are worth roughly $955,000. The exercised options corresponded to prior grants with exercise prices of $4.36 (52,000 shares, expiring July 19, 2032) and $6.00 (25,000 shares, expiring January 31, 2033), and the filing notes a standard vesting schedule for one of the option awards.

Filing Facts

CIK

1796280

Ticker

ORIC

Form

4

Source Type

fda

Accession

0001695028-26-000006

Alert Tier

6